Zoetis (ZTS) Stock Price, News & Analysis

Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Key Stats

• Today's Range: $190.00 to $192.33
• 50-Day Range: $174.82 to $196.48
• 52-Week Range: $144.80 to $201.92
• Volume: 1.28 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $87.15 billion
• P/E Ratio: 36.80
• Dividend Yield: 0.90%
• Price Target: $220.38
• Consensus Rating: Buy

Zoetis Stock Analysis - MarketRank™

Zoetis scored higher than 89% of companies evaluated by MarketBeat, and ranked 130th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Buy

Consensus Rating

Zoetis has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zoetis has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.93%

Earnings Growth

Earnings for Zoetis are expected to grow by 9.93% in the coming year, from $5.84 to $6.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zoetis is 36.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.22.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zoetis is 36.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.79.

Price to Earnings Growth Ratio

Zoetis has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zoetis has a P/B Ratio of 17.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.11% of the float of Zoetis has been sold short.

Short Interest Ratio / Days to Cover

Zoetis has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zoetis has recently decreased by 0.98%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Zoetis has a dividend yield of 0.89%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zoetis has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of Zoetis is 33.14%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zoetis will have a dividend payout ratio of 26.79% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 0.4 / 5
• Environmental Score: -4.66

Percentage of Shares Shorted

1.11% of the float of Zoetis has been sold short.

Short Interest Ratio / Days to Cover

Zoetis has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zoetis has recently decreased by 0.98%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.83

News Sentiment

Zoetis has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Zoetis this week, compared to 12 articles on an average week.

Search Interest

Only 22 people have searched for ZTS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zoetis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.16% of the stock of Zoetis is held by insiders.

Percentage Held by Institutions

92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZTS Stock Analysis - Frequently Asked Questions

How have ZTS shares performed this year?

Zoetis' stock was trading at $197.37 at the beginning of 2024. Since then, ZTS stock has decreased by 3.2% and is now trading at $190.99.
View the best growth stocks for 2024 here.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Tuesday, August, 6th. The company reported $1.56 EPS for the quarter, topping analysts' consensus estimates of $1.49 by $0.07. The business's revenue was up 8.3% compared to the same quarter last year.
Read the conference call transcript.

Does Zoetis have any subsidiaries?

Zoetis subsidiaries include these companies: Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and others.

Who are Zoetis' major shareholders?

Zoetis' top institutional shareholders include SG Americas Securities LLC (0.03%), Neville Rodie & Shaw Inc. (0.03%), AMF Tjanstepension AB (0.02%) and Jacobs & Co. CA (0.02%). Insiders that own company stock include Kristin C Peck, Heidi C Chen, Roxanne Lagano, Willie M Reed, Robert J Polzer, Glenn David, Roman Trawicki and Gregory Norden.
View institutional ownership trends.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

Company Calendar

• Ex-Dividend for 9/4 Dividend: 7/18/2024
• Last Earnings: 8/06/2024
• Dividend Payable: 9/04/2024
• Today: 10/03/2024
• Next Earnings (Confirmed): 11/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ZTS
• CUSIP: 98978V10
• CIK: 1555280
• Web: www.zoetis.com
• Phone: (973) 822-7000
• Fax: 302-655-5049
• Employees: 14,100
• Year Founded: 2012

Price Target and Rating

• Average Stock Price Target: $220.38
• High Stock Price Target: $237.00
• Low Stock Price Target: $196.00
• Potential Upside/Downside: +15.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $5.19
• Trailing P/E Ratio: 36.76
• Forward P/E Ratio: 32.67
• P/E Growth: 2.99
• Net Income: $2.34 billion
• Net Margins: 26.29%
• Pretax Margin: 32.46%
• Return on Equity: 50.67%
• Return on Assets: 17.88%

Debt

• Debt-to-Equity Ratio: 1.32
• Current Ratio: 3.45
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $8.92 billion
• Price / Sales: 9.77
• Cash Flow: $6.29 per share
• Price / Cash Flow: 30.34
• Book Value: $10.87 per share
• Price / Book: 17.55

Miscellaneous

• Outstanding Shares: 456,295,000
• Free Float: 455,565,000
• Market Cap: $87.06 billion
• Optionable: Optionable
• Beta: 0.88